A First-Choice Treatment for the Inpatient Management of Stabilized Systolic HF Patients: An Evidence-Based Approach
Industry Webcast Sponsored by Novartis Pharmaceuticals Corporation; Not for CME/CE Credit
Prevalence of heart failure (HF) is on the rise. Patients hospitalized with heart failure with reduced ejection fraction (HFrEF) are at considerable risk for readmission and mortality. This program will review the opportunity to reassess and influence the trajectory of these patients’ disease through inpatient initiation of a medication shown to help prevent rehospitalization due to HFrEF, reduce patient CV mortality, and improve patients’ quality of life. This program will review mechanistic evidence and provide rationale for its in-hospital initiation.
This content is developed exclusively by or on behalf of the industry sponsor; it is not reviewed or associated with Pri-Med and Pri-Med does not endorse or sanction any third-party content.